Table 2.
Use of health services among Louisiana Medicaid members filling naloxone under the standing order, by encounter type, 2017 to 2019 (n = 1912)
| Variable | Any n (%) | Opioid-related n (%) | Median (IQR) |
|---|---|---|---|
| Within 30 d prior to filling naloxone prescription | |||
| Any health service contact | 1586 (83.0) | 391 (20.4) | - |
| Primary care | 1045 (54.7) | 132 (6.9) | - |
| Behavioral health services | 449 (23.5) | 204 (10.7) | - |
| Emergency department | 436 (22.8) | 25 (1.3) | - |
| Inpatient hospitalization | 290 (15.2) | 99 (5.2) | - |
| Within 60 d prior to filling naloxone prescription | |||
| Medication for opioid use disordera | - | 242 (12.7) | - |
| Prescription opioid analgesic | - | 815 (42.6) | - |
| Maximum daily morphine milligram equivalent | - | 37.5 (20.0–67.5 mg) | |
| Within 90 d after filling a naloxone prescription | |||
| Emergency department visit for overdose | - | 19 (1.0) | - |
Notes: Some patients may have had multiple visits of different kinds within the 30 d prior to filling naloxone prescription. For members filling naloxone multiple times, the first prescription was used as the index prescription for this analysis.
a
Includes buprenrphine or extended-release injectable naltrexone. Methadone was not covered by Louisiana Medicaid for substance use disorder treatment during the study period.